Seattle Genetics (SGEN - Analyst Report) recently presented data from studies conducted on Adcetris. Data was presented at the 12th International Conference on Malignant Lymphoma (ICML).
Seattle Genetics is conducting an investigator-sponsored phase II study in patients with relapsed or refractory Hodgkin lymphoma (HL) to examine whether Adcetris can replace the combination chemotherapy regimen (ifosfamide, carboplatin and etoposide - ICE) or be used in sequential administration with ICE to increase the rate of pre-transplant FDG-PET normalization (PET-N). Out of 33 patients that completed this program, 26 patients achieved complete remission.
Seattle Genetics is conducting a phase II study which is evaluating Adcetris in CD30-positive non-Hodgkin lymphoma. Out of 22 patients whose response could be evaluated, 6 experienced complete remission and 2 partial remissions.
Seattle Genetics had presented encouraging phase I data on Adcetris in mature T-cell lymphoma (MTCL) patients at the American Society of Hematology (ASH) annual meeting in Dec 2012. The study showed 100% objective response rate, which includes 88% complete remissions.
Currently, a global phase III study (ECHELON-2) is ongoing. Adcetris plus chemotherapy is being evaluated for the front-line treatment of CD30-positive MTCL including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas. The randomized, double-blind, controlled study will enroll roughly 300 patients and will be conducted in North America, Europe and Asia.
Seattle Genetics’ Adcetris was approved by the FDA in Aug 2011 for the treatment of patients with HL after failure of ASCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for sALCL in treatment-experienced patients.
Seattle Genetics carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. , Jazz Pharmaceuticals (JAZZ - Analyst Report) and Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy).